306 related articles for article (PubMed ID: 10203263)
1. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
Norton L
Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
[TBL] [Abstract][Full Text] [Related]
2. Evolving concepts in the systemic drug therapy of breast cancer.
Norton L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense chemotherapy for primary breast cancer.
Kümmel S; Rezai M; Kimmig R; Schmid P
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
[TBL] [Abstract][Full Text] [Related]
4. What can be expected from the next generation of adjuvant breast cancer treatment?
Piccart-Gebhart M
Semin Oncol; 1999 Feb; 26(1 Suppl 3):22-5. PubMed ID: 10203267
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
6. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
8. The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
Hudis CA
Semin Oncol; 1999 Feb; 26(1 Suppl 2):1-5. PubMed ID: 10190778
[TBL] [Abstract][Full Text] [Related]
9. New approaches to adjuvant chemotherapy for breast cancer.
Hudis C
Pharmacotherapy; 1996; 16(3 Pt 2):88S-93S. PubMed ID: 8726587
[TBL] [Abstract][Full Text] [Related]
10. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
Nagykálnai T
Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
Poste G
Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
[TBL] [Abstract][Full Text] [Related]
13. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
14. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
15. Implications of the new biology for therapy in breast cancer.
Sledge GW
Semin Oncol; 1996 Feb; 23(1 Suppl 2):76-81. PubMed ID: 8614850
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for breast cancer--"one fits all"?
Bergh J
Breast; 2005 Dec; 14(6):564-9. PubMed ID: 16243525
[TBL] [Abstract][Full Text] [Related]
17. Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?
Hayes DF
Breast; 2009 Oct; 18 Suppl 3():S131-4. PubMed ID: 19914531
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
19. Current status of dose-dense chemotherapy for breast cancer.
Seidman AD
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():78-83. PubMed ID: 16273358
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
